Talon Extension study:
A 56-week phase 111b/IV, open label, one-arm extension study to assess the efficacy and safety of brolucizumab 6mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study.
Principal Investigator – Professor McAllister
For further information about this study please visit the Clinical Trials Registry (NCT04597632)
or contact the Clinical Trials Office on (08) 9381 0750 or email lionsvisiontrials@lei.org.au